688553 汇宇制药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.743-0.6458.3983.7336.844
总资产报酬率 ROA (%)2.020-0.4906.6063.1195.924
投入资产回报率 ROIC (%)2.260-0.5477.3413.4716.657

边际利润分析
销售毛利率 (%)76.39979.60383.41485.92988.202
营业利润率 (%)11.069-6.63531.83813.41515.767
息税前利润/营业总收入 (%)5.474-11.32929.9339.74612.824
净利润/营业总收入 (%)11.688-3.06028.86515.02916.674

收益指标分析
经营活动净收益/利润总额(%)148.652-115.61525.10740.37979.263
价值变动净收益/利润总额(%)-55.405258.93272.54030.73918.969
营业外收支净额/利润总额(%)2.746-2.9730.3625.8921.235

偿债能力分析
流动比率 (X)2.5022.6872.9423.2645.458
速动比率 (X)2.2622.4632.8013.0905.143
资产负债率 (%)27.81925.35223.08019.44713.058
带息债务/全部投入资本 (%)16.65414.44812.78210.2951.708
股东权益/带息债务 (%)488.305578.047672.970863.9905,704.069
股东权益/负债合计 (%)260.388295.327333.743413.795665.802
利息保障倍数 (X)-0.9262.319-14.809-2.161-4.083

营运能力分析
应收账款周转天数 (天)34.69726.37318.07019.1796.594
存货周转天数 (天)389.850374.572310.428440.314352.322